Certara, Inc. (CERT) is a Technology stock trading at $8.44 (as of 2026-08-21), with a market capitalization of $1.29B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara sells biosimulation software and technology-enabled services to help biopharma customers in drug discovery, preclinical and clinical research, regulatory submissions, and market access, and also provides biosimulation technology used by customers to support bringing medicines to patients.
Certara’s profit engine appears to rely on recurring, expanding customer demand for its biosimulation software (Net Revenue Retention Rate 114%, Software Net Revenue Retention Rate 106%, Aggregate Renewal Rate 86%), with growth signals (Book-to-Bill Ratio 1.14) needing to translate into operating profit, which is currently negative (operating margin -4.0).
| Software | $0.1B |
| Tech-Enabled Services | $0.1B |
Business quality (Weak): Customer retention and demand indicators look solid, but profitability is not yet there, with an operating margin of -4.0.
| Price | $8.44 |
| Market Cap | $1.29B |
| EV / EBITDA | 15.5 |
| Price / Book | 1.33 |
| Price / Sales | 3.15 |
| FCF Yield | 6.2% |
| DCF Value (model) | $9.79 |
| DCF Upside vs Price | 16.0% |
| Revenue (TTM) | $418.84M |
| Net Margin | -0.4% |
| Revenue Growth (YoY) | -10.8% |
| EPS Growth (YoY) | 3500.0% |
| FCF Growth (YoY) | -47.4% |
| Altman Z-Score | 1.95 (grey) |
| Sector P/E (Technology) | 34.0 |
| Industry P/E (Business Services) | 30.2 |
| Top Institutional Holder | VANGUARD GROUP INC ($104.98M) |
| Institutional Holders Tracked | 10 |
| Sector | Technology |
| Industry | Business Services |
| CEO | Jon Resnick |
| Employees | 1,487 |
| Country | US |
| IPO Date | 2020-12-11 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.